- Home
- MHN vs PRQR Comparison
MHN vs PRQR Comparison
Compare MHN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHN
- PRQR
- Stock Information
- Founded
- MHN 1997
- PRQR 2012
- Country
- MHN United States
- PRQR Netherlands
- Employees
- MHN N/A
- PRQR N/A
- Industry
- MHN Investment Bankers/Brokers/Service
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- MHN Finance
- PRQR Health Care
- Exchange
- MHN Nasdaq
- PRQR Nasdaq
- Market Cap
- MHN 293.6M
- PRQR 250.7M
- IPO Year
- MHN N/A
- PRQR 2014
- Fundamental
- Price
- MHN $10.30
- PRQR $2.18
- Analyst Decision
- MHN
- PRQR Strong Buy
- Analyst Count
- MHN 0
- PRQR 7
- Target Price
- MHN N/A
- PRQR $8.14
- AVG Volume (30 Days)
- MHN 59.2K
- PRQR 597.4K
- Earning Date
- MHN 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- MHN 4.17%
- PRQR N/A
- EPS Growth
- MHN N/A
- PRQR N/A
- EPS
- MHN N/A
- PRQR N/A
- Revenue
- MHN N/A
- PRQR $18,859,556.00
- Revenue This Year
- MHN N/A
- PRQR N/A
- Revenue Next Year
- MHN N/A
- PRQR N/A
- P/E Ratio
- MHN N/A
- PRQR N/A
- Revenue Growth
- MHN N/A
- PRQR N/A
- 52 Week Low
- MHN $8.69
- PRQR $1.07
- 52 Week High
- MHN $10.81
- PRQR $4.21
- Technical
- Relative Strength Index (RSI)
- MHN 48.49
- PRQR 37.38
- Support Level
- MHN $10.22
- PRQR $1.97
- Resistance Level
- MHN $10.36
- PRQR $2.30
- Average True Range (ATR)
- MHN 0.08
- PRQR 0.21
- MACD
- MHN -0.03
- PRQR -0.09
- Stochastic Oscillator
- MHN 28.57
- PRQR 19.90
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.